Defeating dementia: progress and challenges on the road to 2025

Are we on Track?

#DefeatingDementia

Defeating dementia: progress and challenges on the road to 2025

Dr Richard J. Hodes

Director, National Institute on Aging

#DefeatingDementia

Increases in Alzheimer's and Related Dementias Research Funding

2011	l	2012	2013	l	2014	2015	2	016
	2017		2018	2019				
National Alzheimer's Project Act (NAPA)	\$50 M* redirected within NIH budget	\$40 M* redirected within NIH budget	\$100 M additional approp	\$25 M additional approp	\$350 M additional approp	\$400 M additional approp	\$414 M additional approp	

\$425 M in additional appropriations as of 09/28/18

*one-year money

Years displayed are Fiscal Years

AD and Related Dementias (AD/ADRD) Research

How Much Are We Spending?



NIH Funding to AD/ADRD Has Increased Three Fold!

NIH Research Implementation Milestones drive progress and are Based on Broad Input



https://www.nia.nih.gov/alzheimers/milestones

Translational Programs and Infrastructure for AD and ADRD



Progress over 4 years:

- <u>Centralized data resource</u> established- AMP-AD portal
- <u>All data sharing deliverables</u> met
- Over 100 candidate targets nominated; currently undergoing data-driven prioritization for further preclinical validation
- <u>A variety of experimental</u> validation models developed
- <u>Novel biomarker discovery</u> initiated

	-	-	-
	TCEPD1		PCS4
	TOFDRI		CCN24
U1-A	IGFBRZ		SCINZA
U1-C	BMPR1A	CSRP1	OLFM3
SNRPN	BMPR1B	DAB2IP	SLC22A10
SNRPB	CRHR1	FAM63A	ENAH
PLCD1	TREM2	FURIN	WWTR1
PTRHD1	TYROBP	HMG20B	LRP10
SFRP1	S100A8	IGFBP5	SYP
PPP1R7	S100A9	ISYNA1	PCSK1
DNM3	P2RY2	KIF1C	КМО
RTN4	P2RX7	PADI2	PTTG1IP
EPB41L3	P2RY12	SLC38A2	MLIP
TUBB3	P2RY13	SNAP25	DLGAP1
PLEC	OSMR	STX1A	MOAP1
ANXA5	TLR4	STXBP3	PRKCB
MSN	CR1	SV2B	YAP1
CD44	CSF1R	SYT1	GNA13
LMNA	CX3CR1	SYT12	TRIM56
	SPI1	ZBTB47	
	TNFRSF10A	VGF	
	TNFRSF10B	PLXNB1	

AMP-AD Teams Candidate Targets: preliminary list

Ongoing NIA AD/ADRD and Related Intervention and Prevention Trials (~140)

29 Early-stage Clinical Drug Development (Phase I and Phase II Clinical Trials)	8 Late-stage Clinical Drug Development (Phase II/III and Phase III Clinical Trials)	58 Non- Pharma- cological Interventions	7 Clinical Therapy Development for the Neuro- psychiatric Symptoms of AD/ADRD	34 Care and Caregiver Interventions	3 Delirium/ Post- Operative Cognitive Decline Trials
Amyloid (8) Neurotransmitter Receptors (3) Metabolism and Bioenergetics (4) Vasculature (3) Growth Factors ar Hormones (1) Multi-target (6) Oxidative Stress (2)	Amyloid (6) Vasculature (2) nd	Exercise (14) Diet (5) Cognitive Training (14) Combination Therapy (7) Other (18)	Pharmacological (5 Non-Pharmacologi (2)	o) cal	

Recruitment to a growing AD/ADRD workforce

Over 1/4 of NIA's Alzheimer's and related dementias awardees from Fiscal Year 2015-2018 were either <u>new or early stage</u> investigators

Over 1/3 of NIA's Alzheimer's and related dementias awardees were <u>new to the field</u>

Supplements by Institute/Center



NIA SBIR/STTR Obligations

Dollars in Millions



*estimates





Advanced Search Research Resources Reports and Publications

International Alzheimer's and Related Dementias Research Portfolio (IADRP)

Our database brings together funded research supported by public and private organizations both in the US and abroad all categorized using the Common Alzheimer's and Related Dementias Research Ontology or CADRO.



New IADRP Database

Highlights

💮 Help/User Guide 🛛 🖂 Contact Us

Join IADRP

- Search research by specific related dementias
- Integrate new codes/changes to CADRO
- Link research to related clinical trials, patents and data repositories
- Visualize search results with dynamic charts an graphs



Contacts

- Dr. Charlene Liggins NIA (<u>ligginsc@mail.nih.gov</u>)
- Dr. Jordan Gladman NINDS (Jordan.Gladman@nih.gov)
- Dr. Heather Snyder Alzheimer's Association (<u>hsnyder@alz.org</u>)

What do we need moving forward?

Data sharing – open science framework, target sharing, etc.

New ideas and a larger workforce – interdisciplinary teams, junior investigators

Interventions to test earlier plus hope for later stage disease

– recruitment is key

Better understanding of the biology and overlap with other dementias – improved animal models, risk assessment, disease detection, progression, prediction, resilience, etc.

Improved insights into disease disparities

Expanded caregiver research – benefits to people with dementia as well as their caregivers

Defeating dementia: progress and challenges on the road to 2025

Stéphane Hogan

Head of Sector Neuroscience, European Commission

#DefeatingDementia



EU support for research on dementia

WDC Summit London, 5 December 2018

Stéphane Hogan Head of Sector - Neuroscience Health Directorate DG Research & Innovation

HORIZON 2020

EU support for research - complementary actions



Public partnerships

Harnessing global expertise to fight poverty-related diseases

Global co-operation

One world, one team working to solve common health challenges

> European Commission

EU support for research & innovation (1)



- Funding basic research
 - ERC for frontier research





innovative

medicines

- Marie Skłodowska-Curie Actions (for mobility, training & career development)
- Funding translational research for large-scale collaborative research, including clinical trials
- Innovative Medicines Initiative (IMI) Fostering cooperation between academia and industry (and within industry)



European Commission

EU-funded collaborative brain research



A comprehensive approach



Innovation



A typical EU-funded collaborative project - profile



Collaborative R&I projects (FP7 & Horizon 2020)





Dementia in Horizon 2020 (2014-2018): 91 projects/€195 million

 INnovative, Midlife INtervention for Dementia Deterrence n-MINDD

2020







- Impact of nutritional lipids on neuronal and cognitive performance in aging, Alzheimer's disease & vascular dementia - First randomized controlled trials with 2-year follow-up of patients with prodromal AD
- Validation of a fast and simple peripheral blood diagnostic biomarker kit for Alzheimer's disease
- Prevention of Dementia using mobile phone applications (targeting socio-economically deprived populations)

European Commission

EC support for research & innovation (1)



Human Brain Project



- Supporting research infrastructures
 - The Human Brain project (HBP)

- Fostering European collaboration at national level
 - Joint Programme for Neurodegenerative Disease research (JPND)



- International cooperation for implementation research
 - Global Alliance for Chronic Diseases (GACD): 14 member agencies



Public-private partnerships



Partnership 2008 - 2024 efpia

€2.5 br



IMI: world's largest PPP in life sciences

€2.5 bn

- To improve development of medicines
- Unprecedented inter-industry collaboration and with academia, patients, regulators...
- IMI Alzheimer's disease Joint Platform: EC contribution € 58.2 million



- European Prevention of Alzheimer's Dementia consortium
- Organising mechanistic knowledge of neurodegenerative diseases to improve drug development and therapy



- Investigate value of β -amyloid brain scans as a diagnostic and therapeutic marker for Alzheimer's disease

Jropean Sommission

Public-Public partnerships



- Foster coordination of research activities of 30 Member States and other countries
- Support and align national strategies
- Develop common R&I agenda
- Co-invest in research joint calls: €150m
- Develop international collaboration







Accelerating brain research

Coordinating European brain research & developing global initiatives => EBRA project: European Brain Research Area



- European Brain Council (EBC), JPND, NEURON, Human Brain Project
- Nov. 2018 Oct. 2021 EU funding €2 million
- EBRA will coordinate and foster synergies in brain research
 - integrate EU funded initiatives and foster thematic clusters
 - align brain research strategies and initiate new ones
 - develop international collaboration



Global co-operation



- International funders
- Flexible arrangements
- Common goals defined with researchers
- critical mass
- Sharing tasks, costs, infrastructures & data
- Sharing best practices









Global Research Collaboration for Infectious Disease Preparedness



European Commission







"Open Science, Open Innovation, Open to the World"

> Research and Innovation